In contrast, a Japanese study investigated osimertinib alone or with upfront CNS RT for BrMs from EGFR-mutated NSCLC and reported that both the OS and intracranial PFS were significantly longer with upfront RT compared to with osimertinib alone [144]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.